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The epidermal growth factor receptor (EGFR) has been implicated in the regulation of wound healing. In order to
directly evaluate the role of endogenous EGFR in cutaneous incisional wound healing, we examined EGFR null-
and wild-type skin after injury. By 5 d after wounding, re-epithelialization was complete in all EGFR wild-type
wounds, but in only 40% of EGFR null wounds. Delayed wound closure in EGFR null skin was accompanied by an
increase in edema, longer lasting and more prominent eschar, and increased distance between apposing wound
edges. EGFR altered neutrophil and mast cell inﬁltration, and enhanced angiogenesis. EGFR enhanced epithelial
proliferation during the ﬁrst 3 d following injury, although proliferation was greater in EGFR null wounds at 5 d.
Although migration was decreased in EGFR null keratinocytes cultured with standard medium or in medium sup-
plemented with transforming growth factor-a when compared with controls, the addition of the wound-associated
motogen keratinocyte growth factor eliminated the differences between genotypes. Epithelial migration into the
wound was decreased in EGFR null skin, suggesting that both EGFR-dependent and -independent mechanisms
regulate migration during wound healing. These data demonstrate that EGFR regulates multiple facets of cuta-
neous wound healing, including inﬂammation, wound contraction, proliferation, migration, and angiogenesis.
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Disruption of skin integrity through trauma or disease can
lead to adverse healing outcomes, resulting in significant
patient morbidity and mortality. Optimal healing of burns
and other cutaneous wounds remains a therapeutic chal-
lenge, despite a variety of available treatment modalities. In
addition, mechanisms underlying abnormal wound healing,
as in chronic diabetic ulcers and hypertrophic scars, require
further elucidation in order to improve existing treatments.
Although many aspects of wound healing remain elusive,
it is clear that wound healing includes several phases, the
aggregate of which comprises a continuous and well-or-
chestrated process (Stadelmann et al, 1998; Hunt et al,
2000; Yamaguchi and Yoshikawa, 2001).
A temporary repair of cutaneous injury is accomplished
by the formation of a fibrin clot. Within hours after wound-
ing, an acute inflammatory phase in which neutrophils and
macrophages are recruited to the wound begins (Singer and
Clark, 1999). Fibroblasts and capillaries then invade the
wound site to produce a contractile granulation tissue that
draws the wound edges closer together (Singer and Clark,
1999). Upon dissolution of junctions between keratinocytes,
basement membrane, and extracellular matrix, keratin-
ocytes migrate from the wound margins into the granula-
tion tissue (Singer and Clark, 1999). Keratinocyte pro-
liferation at the wound margin increases behind migrating
keratinocyte tongues (Singer and Clark, 1999). Re-epithe-
lialization is completed when the advancing keratinocyte
tongues meet, at which point keratinocyte migration ceases
(Stadelmann et al, 1998). A final remodeling phase, lasting
up to a year (Singer and Clark, 1999), involves simultaneous
collagen synthesis by fibroblasts and collagen degrada-
tion by matrix metalloproteinases (Stadelmann et al, 1998;
Singer and Clark, 1999).
Although the mechanisms of wound healing have only
been partially elucidated, the receptor tyrosine kinase ep-
idermal growth factor receptor (EGFR) has been implicated
in this process. A transient elevation of EGFR and its ligands
occurs in the skin and other epithelia following injury, which
is believed to contribute to the migratory and proliferative
potential of keratinocytes adjacent to wound margins (re-
viewed in Werner and Grose, 2003). Increased EGFR ex-
pression by gene gun transfection at the time of porcine
partial-thickness incisional wounding accelerates wound re-
epithelialization (Nanney et al, 2000). EGFR-specific tyrosine
kinase inhibitors strongly inhibit transcription of vascular
endothelial growth factor, amphiregulin, keratin 6, and he-
parin-binding EGF-like factor (HB-EGF) (Stoll et al, 1997),
factors that enhance wound healing. Although mice defi-
cient in transforming growth factor (TGF-a) exhibit sub-
stantially normal wound healing (Werner and Grose, 2003),
Abbreviations: aFGF, acidic fibroblast growth factor; bFGF, basic
fibroblast growth factor; BrDU, bromodeoxyuridine; EGFR, epider-
mal growth factor receptor; IL-8, interleukin-8; KGF, keratinocyte
growth factor; MEM, minimal essential medium; TGF-a, transform-
ing growth factor alpha; VEGF, vascular endothelial growth factor
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exogenous application of several EGFR ligands including
TGF-a enhances wound healing. EGFR also stimulates an-
giogenesis in murine skin carcinomas (Casanova et al, 2002)
and other neoplasms (Huang et al, 2002; Karashima et al,
2002), suggesting it might similarly accelerate blood vessel
formation during wound healing. No examination of wound
healing in mice lacking EGFR, which would clarify the role of
EGFR in wound repair, has yet been reported.
In order to directly determine the importance of endog-
enous EGFR expression on wound healing, we have exam-
ined wound repair in EGFR null- and wild-type control
mouse skin. By comparing wound healing in EGFR null- and
wild-type skin grafts, we were able to examine the influence
of EGFR on all phases of wound healing in the absence of
systemic influences. We show that EGFR is an important
regulator of several early events during wound healing. Our
data demonstrate that EGFR is necessary for efficient
wound closure and suggest that cutaneous EGFR expres-
sion accelerates wound healing by regulating edema, in-
flammation, proliferation, and angiogenesis.
Results
EGFR accelerates wound healing Because EGFR null
mice do not survive beyond a few days after birth [11],
wound healing was examined in EGFR null- and wild-type
skin grafts. A full-thickness incision was made through each
graft and the edges apposed using wound clips (Fig 1).
Wound healing was examined between the wound clips at
several time points. Grossly, both EGFR null- and wild-type
wounds were open (incompletely re-epithelialized) 1 d after
incisional wounding (Fig 1). Wound widths in the EGFR null
mice were two to three times that of EGFR wild-type
wounds (Fig 1). This was observed in each of two separate
wounding experiments, although the skin grafting was per-
formed identically with mice from the two genotypes each
time. The separation of apposed wound edges in EGFR null
skin suggests a failure of the contractile function of the
granulation tissue within the wound (Singer and Clark,
1999). Erythema, edema, and eschar were present in the
wounded skin of both genotypes one day after wounding,
although these responses were more pronounced in EGFR
null wounds (Fig 1). Three days after wounding, wound
widths in both EGFR null- and wild-type skin decreased
when compared with 1 d after injury, although the difference
between genotypes was maintained (Fig 1). Wound margin
erythema decreased slightly in both genotypes, whereas
EGFR null wounds remained quite edematous in compar-
ison with wild-type wounds (Fig 1). Five days after wound-
ing, the separation of the wound edges and an increase in
the area of the wound still covered by eschar were apparent
in EGFR null skin when compared with wild-type (Fig 1). By
5 d after wounding, all wounds in EGFR wild-type skin
were closed with resolution of wound margin erythema. In
contrast, wound closure was complete in less than half of
Figure 1
Epidermal growth factor receptor (EGFR) accelerates wound re-epithelialization. Prior to wounding, EGFR null- and wild-type grafts were well
healed and growing abundant hair (unwounded mice). Both EGFR null- and wild-type mice show open (incompletely re-epithelialized) wounds 1 d
after incisional wounding. Erythema is present in the wound margins of both genotypes. However, the wound widths in EGFR null skin are two to
three times that of EGFR wild-type skin. Three days after wounding, wound width in EGFR null skin decreased slightly when compared with day 1.
Wounds in EGFR wild-type mice, however, showed wound closure (mouse on right) or substantially reduced wound width (mouse on left). Wound
margin erythema decreased slightly in both genotypes. Five days after wounding, wounds in EGFR null mice appeared similar to wounds 3 d after
injury. In contrast, all wounds in EGFR wild-type mice were closed with resolution of wound margin erythema.
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EGFR null skins, with residual erythema and scabbing
(Fig 1).
The histology of EGFR null- and wild-type wounds cor-
related with their gross appearance. One day after wound-
ing, both EGFR null- and wild-type wounds demonstrated
prominent eschar formation, whereas edema was pro-
nounced in EGFR null wounds (Fig 2A, B). Wound closure,
defined by complete re-epithelialization, was incomplete in
the skin of both genotypes (Fig 2A, B and Table I). By 3 d,
wound closure was complete in more than 50% of EGFR
wild-type wounds (Fig 2D and Table I). In contrast, wound
closure had occurred in only 20% of EGFR null wounds
(Fig 2C and Table I). Three days after injury, EGFR wild-type
wounds lacking complete re-epithelialization showed es-
char resolution and considerable narrowing of the wound
(data not shown). In contrast, open EGFR null wounds re-
tained prominent eschar with only slight narrowing of the
defect (Fig 2C). Additionally, histological examination of
EGFR null wounds revealed separation of tissue located in
the deep dermis, a finding not detected in EGFR wild-type
wounds (Fig 2C, D). This tissue separation imparted a friable
appearance to the EGFR null dermis. Surprisingly, however,
collagen and fibronectin, as detected by van Gieson’s stain
and immunoblotting, respectively, were not decreased in
EGFR null skin (data not shown). In contrast to published
reports (Mimura et al, 2004), fibronectin expression was
increased in both EGFR null skin and in EGFR null keratin-
ocytes in culture when compared with wild-type controls
(data not shown).
Re-epithelialization was complete in all EGFR wild-type
wounds by 5 d after wounding (Fig 2F and Table I). In con-
trast, wound closure was complete in less than half of EGFR
null skins (Fig 2E and Table I). Fourteen days after wound-
ing, wound closure was complete in all EGFR null- and
wild-type skin grafts (Table I, Fig 2G, H ). These results
demonstrate a substantial delay in wound closure in EGFR
null skin, which was accompanied by increased edema,
erythema, and eschar in the absence of the receptor. Thus,
endogenous expression of EGFR in the skin is necessary for
efficient wound closure after incisional injury.
EGFR increases wound-induced proliferation Keratin-
ocyte proliferation behind migrating keratinocyte tongues is
essential for effective wound re-epithelialization. EGFR ac-
tivation has been implicated in stimulating epithelial prolif-
eration after wounding (Nakamura et al, 2001). To determine
the effects of abrogation of EGFR on keratinocyte prolifer-
ation in response to incisional wounding, bromodeoxyuri-
dine (BrDU)-labeled S-phase keratinocytes were quantified
in EGFR null- and wild-type wounded skin prior to the
completion of re-epithelialization. Epithelial proliferation
adjacent to the wound increased in both EGFR null- and
wild-type skin 1 d following wounding (Table II) (Fig 3A, B).
However, the highly proliferative epidermal segments in EGFR
wild-type wounded skin contained almost twice as many
BrDU-positive nuclei than those in EGFR null skin at both 1
and 3 d after wounding (Fig 3A–D, Table II). The increased
proliferation was accompanied by epidermal hyperplasia
adjacent to the wound that was more pronounced in EGFR
wild-type skin than in EGFR null skin (Fig 3A–D). Interest-
ingly, 5 d after wounding, EGFR null skin exhibited a sig-
nificant surge in epithelial proliferation with respect to day 3,
a phenomenon absent in EGFR wild-type wounds (Table II,
Fig 3E, F ).
Figure 2
Epidermal growth factor receptor (EGFR) accelerates wound re-
epithelialization. EGFR null (A, C, E, G) and wild-type skin grafts (B, D,
F, H) were wounded and cross-sections of the wounds were removed 1
(A, B), 3 (C, D), 5 (E, F ), or 14 d (G, H) later. One day after incisional
wounding (A, B), hematoxylin- and eosin-stained skin from both EGFR
null- and wild-type grafts showed open wounds, eschar formation, and
acute inflammation. Three days after injury, re-epithelialization had be-
gun in EGFR null skin (C), with some narrowing of the wound. Prom-
inent eschar remained. Neutrophil density was unchanged. Three days
after wounding, EGFR wild-type skin (D) showed resolution of the es-
char, nearly complete re-epithelialization, and reduced acute inflam-
mation. Five days after wounding, wound width in EGFR null skin (E )
was similar to that of wounds 3 d after injury. EGFR wild-type wounds
(F ) were closed. Fourteen days after injury, all EGFR null- and wild-type
skin showed wound closure, marked decrease in neutrophil density,
and erythema resolution. Scale bar¼ 500 mm.
Table I. EGFR accelerates wound re-epithelialization
Time after
wounding (d)
Re-epithelialized wounds
EGFR/ EGFRþ /þ
1 0/8 (0%) 0/5 (0%)
3 1/5 (20%) 5/9 (56%)
5 2/5 (40%) 7/7 (100%)
14 2/2 (100%) 4/4 (100%)
Wound re-epithelialization was determined by histologic examination
and is reported as the proportion of re-epithelialized wounds relative to
the total number of wounds. The percentage of re-epithelialized wounds
is reported in parentheses.
EGFR, epidermal growth factor receptor.
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As indicated in the methods section, only basal BrDU-
labeled cells were counted. Proliferation was largely limited
to the basal layer away from the wound, but suprabasal
proliferation was common adjacent to the wound in the first
5 d post-wounding. The majority of proliferating cells ad-
jacent to the wound 1 and 5 d post-wounding were basal
cells in both EGFR null- and wild-type skin. Suprabasal
proliferating cells made up the majority of proliferating cells
3 d post-wounding, with about 60% of proliferating cells in
suprabasal cell layers in both genotypes. Thus, EGFR con-
tributed to wound-induced epithelial proliferation early in
wound healing. Additional proliferation-stimulating mecha-
nisms, however, must be operative in EGFR null wounds,
mechanisms sufficient to effect eventual wound closure.
Wound-induced keratinocyte migration is decreased in
the absence of EGFR In concert with proliferation, kera-
tinocyte migration is necessary for successful wound re-
epithelialization. EGFR activation enhances keratinocyte
migration in vitro (reviewed in Hudson and McCawley,
1998). To better determine the effect of EGFR on keratin-
ocyte migration in vivo following wounding, the lengths of
migrating epithelial segments in open wounds were meas-
ured at various time points after injury. In contrast to our
expectations, no significant difference in keratinocyte mi-
gration between EGFR null- and wild-type skin was detect-
ed in vivo 1 d post-wounding (Table III). Although the mean
length of migrating epithelial segments in EGFR null skin
was only 45% that of EGFR wild-type skin at 3 d post-
wounding, this difference was only marginally significant
(p¼ 0.09, Table III). In order to assess the influence of mo-
lecular interactions between EGFR and other growth factor
receptor-mediated signaling in wound healing-associated
keratinocyte migration, migration assays were performed
using EGFR null- and wild-type keratinocytes in vitro. Nu-
merous growth factors and their corresponding receptors
are believed to contribute to the epithelial migration that is
necessary for wound closure, including keratinocyte growth
factor (KGF) (Werner and Grose, 2003). KGF appeared to be
a similarly potent motogen for both EGFR null- and wild-
type cells, with keratinocytes of both genotypes migrating
similar distances at 24 and 48 h after wounding (Table IV,
Fig 4E, F). In contrast to our results with KGF-containing
medium, EGFR enhanced the migration of keratinocytes
cultured in both standard medium and TGF-a-supplement-
ed medium (Fig 4A–D). EGFR wild-type keratinocytes cul-
tured in standard growth medium migrated more than three
times the distance when compared to EGFR null cells 48 h
after wounding (Table IV). Similarly, TGF-a stimulated EGFR
wild-type but not EGFR null keratinocyte migration (Fig 4C,
D and Table IV). Thus, although activation of EGFR en-
hanced keratinocyte migration in vitro, the presence of non-
EGFR growth factor ligands such as KGF in the wound site
may have a dominant effect on stimulating keratinocyte
migration during wound healing in vivo.
EGFR regulates acute inﬂammation Neutrophils play an
important role in the inflammatory phase of wound healing,
cleansing the wound of cellular debris and releasing
cytokines necessary for the paracrine activation of growth
factor expression (Hubner et al, 1996; Yamaguchi and Yos-
hikawa, 2001). A paucity of literature exists in regard to the
role of EGFR in the acute inflammatory process following
Table II. EGFR increases wound-induced proliferation
Days after
wounding
Number of BrDU-labeled
basal keratinocytes
EGFR/ EGFRþ /þ
1 56.8  10.4 99.2  19.8
3 29.8  6.6 59.9  24.3
5 64.0  5.3 29.5  14.6
Tissue sections were immunohistochemically labeled for BrDU as de-
scribed in the methods section. BrDU-labeled nuclei were counted in
proliferating basal keratinocyte segments adjacent to the wound. A
proliferating segment was defined as beginning with the BrDU-labeled
keratinocyte most proximal to the wound margin and ending with the
BrDU-labeled keratinocyte at which the BrDU labeling index fell below
10%. The mean number of BrDU-labeled basal keratinocytes for prolif-
erating segments  standard errors are shown. Sample size is X4.
The mean BrDU-labeled keratinocyte count is significantly different
from that of the corresponding EGFR wild-type control where pp0.05
using a Student’s t test.
EGFR, epidermal growth factor receptor; BrDU, bromodeoxyuridine.
Figure3
Epidermal growth factor receptor (EGFR) increases wound-in-
duced proliferation. One day after incisional wounding, immunohisto-
chemically stained skin immediately adjacent to EGFR null wounds (A)
showed fewer bromodeoxyuridine (BrDU)-labeled basal keratinocytes
when compared with EGFR wild-type skin (B). EGFR null skin had a
notably thinner epidermis at all time points when compared with EGFR
wild-type skin. Three days after injury, EGFR null skin (C) continued to
show fewer BrDU-labeled basal keratinocytes when compared with
EGFR wild-type skin (D). BrDU-labeling 3 d after wounding was de-
creased in both genotypes when compared with day 1 (A, B). Five days
after wounding, EGFR null skin showed a surge in BrDU basal kera-
tinocyte labeling (E ), whereas fewer BrDU-labeled basal keratinocytes
were seen in EGFR wild-type skin (F ). Scale bar¼ 100 mm.
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cutaneous wounding. To determine whether EGFR regu-
lates acute inflammation during wound healing, neutrophils
were immunohistochemically labeled and quantified at var-
ious time points following wounding. To control for the pos-
sibility that acute inflammation induced by the grafting
procedure had not subsided by the time of wounding, ne-
utrophils were also quantified in grafted and non-grafted
unwounded skin. Neutrophilic density was similarly low in
EGFR null- and wild-type grafts prior to wounding (Table V),
suggesting that the inflammation induced by the grafting
procedure had fully subsided by the time of wounding. Ne-
utrophil density increased significantly in both EGFR null-
and wild-type skin 1 day after wounding (Table V). EGFR null
wounds contained, however, 57% more neutrophils per
high power field when compared with wild-type wounds.
Three days after wounding, neutrophil density decreased
from day 1 in both EGFR null- and wild-type wounds and
remained stable thereafter (Table V).
Mast cells regulate acute and chronic inflammation by
release of various mediators and by production of inflam-
matory cytokines (Metcalfe et al, 1997). Following acidic
toluidine blue staining, mast cells were quantified in EGFR
null- and wild-type skin. Mast cells in both genotypes ap-
peared in greatest number immediately subjacent to the
dermal–epidermal junction, an area rich in small blood ves-
sels, also consistent with other reports (Table V) (Cowen
et al, 1979; Tharp, 1989). The number of mast cells present
in unwounded EGFR null graft skin was not significantly
different from wild-type controls (Table V). Mature mast cells
in both EGFR null- and wild-type wounds were sparse ad-
jacent to the wound, but progressively increased in number
with increasing distance from the injury, consistent with
other reports (Wichmann, 1955; Metcalfe et al, 1997). One
day after wounding, mast cell density increased in EGFR
wild-type, but not EGFR null wounds (Table V). Mast cell
numbers did not increase in EGFR null wounds until 3 d
after wounding (Table V). By 5 d after wounding, mast cell
numbers were similarly increased in wounds of both gen-
otypes (Table V).
Macrophages appear at the wound site within hours after
injury and become the dominant inflammatory cell type
2 d after wounding (Stadelmann et al, 1998). Following
immunohistochemical labeling, macrophages were quanti-
fied at several time points after wounding. Unlike ne-
utrophilic and mast cell numbers, EGFR did not significantly
affect macrophage density (data not shown). These results
suggest that EGFR differentially affects leukocyte subsets,
suppressing neutrophil and increasing mast cell popula-
tions, but not affecting macrophages.
EGFR increases wound-induced angiogenesis Angio-
genesis is necessary to maintain the granulation tissue
formed during wound healing. Although the influence of
EGFR on tumor angiogenesis has become clearer in the last
several years (Casanova et al, 2002; Huang et al, 2002;
Karashima et al, 2002), its role in angiogenesis during
wound healing remains largely unknown. In order to deter-
mine the effects of EGFR on angiogenesis during wound
healing, we used immunofluorescence microscopy to quan-
tify microvessel density in EGFR null- and wild-type skin at
several time points after incisional wounding. To control for
the possibility that the grafting procedure itself induced new
Table III. Migration is decreased 3 d after wounding
in EGFR null skin
Time after
wounding (d)
Migration distance (mm)
EGFR / EGFR þ /þ
1 0.234  0.046 0.200  0.047
3 0.166  0.033 0.306  0.100
5 0.108  0.008 N/A
Mean migration  standard error in mm is reported. Migration was
measured in each wound margin from the migrating tip of basal kera-
tinocyte most proximal to the open wound site, distally to the first-en-
countered BrDU-stained keratinocyte. This BrDU-positive keratinocyte
was defined as the beginning of the proliferating segment of basal ker-
atinocytes. Only wounds with incomplete re-epithelialization were as-
sessed. Data are from two wounding experiments, which had similar
results. For day 1, NX8 wound margins. For day 3, NX5. For day 5,
N¼2.
Value is significantly different from the corresponding wild-type con-
trol using a one-tailed Student’s t test, where p¼0.09.
EGFR, epidermal growth factor receptor; BrDU, bromodeoxyuridine;
N/A, not available.
Table IV. EGFR increases the migration of keratinocytes cultured in standard medium
and TGF-a-supplemented medium, but not in KGF-supplemented medium
Culture medium additive
Migration distance (lm)
24 h 48 h
EGFR/ EGFRþ /þ EGFR/ EGFRþ /þ
None 29  10 (11) 54  6 (20) 45  13 (18) 164  13 (62)
KGF 213  26 (84) 210  32 (78) 248  3 (100) 264  3 (100)
TGF-a 23  10 (12) 139  10 (48) 55  13 (21) 294  19 (100)
EGFR null- and wild-type keratinocytes were cultured in standard medium, KGF-containing medium, and TGF-a-containing medium. Wells were
photographed and migration distance measured at 0, 1, and 2 d after wounding. NX5. This experiment is representative of two performed. Mean
migration distance in mm (incorporating migration of both keratinocyte margins)  standard error is shown. Percentage of initial scratch width (day 0)
covered with migrating keratinocytes is shown in parentheses.
The mean is significantly different from the corresponding EGFR wild-type control, where pp0.05 using a Student’s t test.
The mean is significantly different from the corresponding control cultured without the addition of the growth factor, where pp0.05 using a Student’s
t test.
EGFR, epidermal growth factor receptor; TGF-a, transforming growth factor alpha; KGF, keratinocyte growth factor.
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vessel formation, vessel density was assessed in EGFR
null- and wild-type mice with unwounded graft skin. Mean
microvascular density in unwounded skin 19 d after grafting
was similar in EGFR null- and wild-type skin. Although mi-
crovessel density in EGFR null wounds did not change sig-
nificantly following wounding, microvessel density in EGFR
wild-type skin 3 d after injury increased to nearly four times
that of EGFR null skin (Table VI). Five days after wounding,
microvessel density in EGFR wild-type wounds returned to
the day 1 level. Since newly formed blood vessels arose
from the host tissue, these results suggest that EGFR is
required for wound-induced angiogenesis through a par-
acrine mechanism.
Discussion
Our data indicate that EGFR stimulates cellular events
critical to wound healing. Keratinocyte proliferation, re-
epithelialization, inflammation, and angiogenesis were all
regulated to some extent by EGFR. Although EGFR con-
tributed to cutaneous wound repair, it was not necessary for
this process to occur. Although delayed, wound re-epithe-
lialization was eventually completed in the absence of the
receptor.
Endogenously expressed EGFR stimulated keratinocyte
proliferation adjacent to the wound margin in the first 3 d
after wounding, consistent with reports of prolonged EGFR
activation for at least several days after burn injury in in-
completely re-epithelialized wounds (Wenczak et al, 1992).
Since a large proportion of EGFR wild-type wounds were
closed 3 d after wounding, wound closure-associated
downregulation of EGFR activity may be responsible for
the diminished keratinocyte proliferation that occurred be-
ginning at 3 d. Our results also suggest that EGFR-inde-
pendent signaling mechanisms may become dominant by
5 d after wounding in EGFR null skin, resulting in the surge
of proliferating keratinocytes observed in EGFR null wounds
5 d after injury. In support of this hypothesis, we found that
KGF, acidic fibroblast growth factor (aFGF), and basic fib-
roblast growth factor (bFGF) are potent mitogens in EGFR
null- and wild-type keratinocytes (Dlugosz et al, 1997 and
data not shown). Alternatively, EGFR could have a sup-
pressive effect on proliferation at later times after wounding,
since proliferation in EGFR null wounds exceeded that of
EGFR wild-type wounds at 5 d.
Multiple reports document that EGFR activation upon the
addition of ligand enhances epithelial migration in vitro fol-
lowing wounding (reviewed in Hudson and McCawley,
1998). Consistent with these reports, we found that EGFR
null keratinocytes exhibited impaired migration when cul-
tured in standard growth medium or in TGF-a-supplemented
Figure 4
Epidermal growth factor receptor (EGFR) increases the migration
of keratinocytes cultured with standard growth medium and trans-
forming growth factor (TGF)-a. EGFR null- (A, C, E) and wild-type (B,
D, F ) cultured keratinocytes were wounded by scratching the culture
dish surface with a pipette tip and photographed 24 h later. Keratin-
ocytes were cultured in standard growth medium (A, B), standard me-
dium with TGF-a (C, D), or in standard medium with keratinocyte
growth factor (KGF) (E, F ) in the presence of mitomycin C. Photographs
were taken in at least five marked spots for each group at several time
points for each of several experiments performed. Images shown are
representative of results.
TableV. EGFR regulates wound-induced inﬂammation
Days after
wounding
Neutrophils Mast cells
EGFR/ EGFRþ /þ EGFR/ EGFRþ /þ
Control 9.6  5.7 2.6  0.8 29.3  3.4 24.0  0.8
1 105.8  11.4 67.5  10.9 25.9  1.2 38.5  1.3
3 29.7  10.1 21.8  5.2 45.5  1.6 31.6  1.4
5 30.8  5.3 25.3  10.3 48.5  2.2 53.1  1.3
Neutrophils and mast cells were counted in at least four  40 microscopic fields under and adjacent to the wound following immunohistochemistry
for Ly-6G or toluidine blue staining, respectively. Mean number of neutrophils and mast cells per field  standard errors are shown. NX20 fields except
for neutrophil measurements in EGFR null skin at day 5, where N¼ 5.
The mean cell count is significantly different from the corresponding EGFR wild-type wounds, where pp0.05 using a Student’s t test. Significantly
different from the corresponding wild-type control using a one-tailed Student’s t test, where p¼ 0.09.
EGFR ENHANCES WOUND HEALING 987123 : 5 NOVEMBER 2004
medium. The addition of KGF to the culture medium, how-
ever, stimulated EGFR null keratinocyte migration to the
same extent as in the wild-type controls. Keratinocyte mi-
gration was decreased in EGFR null wounds in vivo only at
3 d post-wounding and only with marginal statistical signif-
icance. High inter-animal variation or small sample size
most likely masked highly significant differences in cell mi-
gration between genotypes. Alternatively, KGF or other
growth factor motogens acting independent of EGFR may
be dominant in inducing migration during wound healing.
Tokumaru et al (2000) has, in fact, reported that an inhibitor
of HB-EGF shedding decreased keratinocyte migration in
full-thickness mouse skin wounds.
An early event in wound healing, recruitment of ne-
utrophils from the peripheral circulation, begins shortly after
wounding. Genetic ablation of EGFR increases neutrophil
density 1 d after wounding. Since these cells are host-de-
rived, the effect of EGFR abrogation on inflammation must
be indirect. It would be of interest to determine whether the
lack of EGFR changes the chemokine expression pattern.
We previously showed that EGFR null hair follicles do not
involute normally during the transition between anagen and
catagen, but instead are invaded and consumed by inflam-
matory cells (Hansen et al, 1997). Although this study was
performed prior to inflammatory cell invasion of hair follicles
and the increased neutrophil infiltration of wounded EGFR
null skin was not peri-follicular, both studies demonstrate a
predisposition to inflammation in EGFR null skin under dif-
fering conditions. The higher number of neutrophils might
also have resulted from the delayed wound closure, which
could create a pro-inflammatory stimulus. Alternatively,
EGFR may alter the temporal pattern of neutrophilic infil-
tration after wounding. Neutrophil density in EGFR wild-type
skin may have peaked prior to 24 h after wounding. In sup-
port of this second hypothesis, we found that EGFR abro-
gation delayed neutrophilic infiltration in UV-induced skin
injury (unpublished observations). In addition, a delay in the
infiltration of mast cells, which are important regulators of
immune and non-immune inflammation, was detected in
skin lacking EGFR.
Angiogenesis is essential to rapid wound re-epithelia-
lization, allowing an optimal influx of micronutrients, oxygen,
and growth factors. Few studies have examined the effect
of EGFR on angiogenesis during cutaneous wound healing,
although several reports implicate EGFR-enhanced angio-
genesis in murine models of skin and prostate carcinoma
(Casanova et al, 2002; Karashima et al, 2002). We found a
significantly greater microvessel density in EGFR wild-type
skin when compared with EGFR-null wounds 3 d after
wounding, suggesting that EGFR enhances angiogenesis.
The reduced angiogenesis observed in the EGFR null mice
may be a result of reduced expression of vascular end-
othelial growth factor (VEGF), since expression of this factor
is induced by EGFR ligands in many cell types (Rak et al,
2000). No differences in VEGF expression, however, were
revealed by immunohistochemical staining of EGFR null-
and wild-type wounds (data not shown).
Our research suggests that EGFR has pleiotropic func-
tions during wound healing. We found that EGFR is neces-
sary for efficient keratinocyte proliferation, re-epithelia-
lization, inflammation, and angiogenesis during wound re-
pair. We previously reported abnormal hair follicle develop-
ment and involution in EGFR null skin. Our finding of
separated and friable tissue deep to the wound in EGFR null
skin suggests that additional dermal pathology exists.
EGFR activation stimulates rapid epithelial proliferation,
necessary for rapid re-epithelialization of cutaneous
wounds and for limiting the potential for destructive wound
infection. Our data demonstrated that EGFR has profound
effects on acute inflammation through the regulation of ed-
ema, recruited neutrophils, and mast cells. This report im-
plicates EGFR in enhanced angiogenesis during wound
healing. These results have implications for developing
therapeutic modalities in the treatment of cutaneous
wounds. EGFR null skin could provide a model to study
agents designed to enhance wound healing, since EGFR is
likely downregulated within a couple of days of wounding
due to upregulation of ligand expression. Additionally, EGFR
stimulation might be particularly useful in treating cutaneous
wounds compromised by poor peripheral vasculature, since
it strongly enhanced angiogenesis. In mice, advanced age
is associated with delayed upregulation of EGFR and EGFR
ligands during wound healing (Ashcroft et al, 1997). Thus,
our results may also have implications for the understanding
and treatment of impaired wound healing in the aged. The
effectiveness of targeting EGFR pathways in the treatment
of cutaneous wounds lies in determining the temporal se-
quence of molecular events regulating wound healing, since
the timing of growth factor application may be as important
for rapid wound closure as the type of growth factor and its
dosage. Targeting EGFR pathways soon after wounding
may be necessary for a positive response, since our data
reveals that EGFR’s effects occur in the first few days after
wounding.
Materials and Methods
Animals EGFR null mice were genotyped using polymerase chain
reaction as described elsewhere (Threadgill et al, 1995). Pieces of
full-thickness, hairless skin from 2–5-d-old EGFR null- or wild-type
mice were grafted onto male athymic nude mice as described
previously (Hansen et al, 1997). The donor skin graft was oriented
in a reverse direction (i.e., head to tail) on a wound created by
removing a circular piece of full-thickness skin from the dorsum of
TableVI. EGFR increases wound-induced angiogenesis
Days after
wounding
Microvessel numbers
EGFR/ EGFRþ /þ
1 12.0  4.1 11.3  3.1
3 6.2  3.1 25.9  6.8
5 8.3  4.4 10.4  3.5
14 11.5  3.5 17.2  7.8
Microvessel density was determined using immunofluorescence mi-
croscopy. The number of blood vessels was quantified in a  20 micro-
scopic field centering on the wound site. Mean numbers of vessels per
 20 microscopic field  standard errors and sample sizes are shown.
NX4, except for EGFR-null wounds 14 d after wounding, where N¼ 2.
The mean is significantly different from the corresponding EGFR wild-
type wounds where pp0.06 using a Student’s t test.
EGFR, epidermal growth factor receptor; BrDU, bromodeoxyuridine.
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the host animal. The junction of the graft and host skin was then
sealed with Superglue and mice were bandaged with Vetwrap (3M,
St. Paul, Minnesota). After allowing the grafts to heal for several
weeks, the skin grafts were shaved with electric clippers to prepare
for wounding. Straight scissors were used to make a 2–3 cm full-
thickness incision longitudinally through the center of each graft.
The wound edges were approximated with wound clips. The
wounds were removed 1, 3, 5, or 14 d after wounding. One hour
prior to euthanasia, the mice were injected intraperitoneally with
250 mg BrDU per g body weight. Two to three cross-sections of
each wound were removed between the wound clips for histolog-
ical processing. Tissues were fixed in 70% ethanol, processed,
and embedded in paraffin or flash frozen in liquid nitrogen. Two
experiments were performed, each with 3 or 4 mice assigned to
each group and time point. These experiments were performed in
compliance with the institutional animal care and use committee.
Histochemistry, immunohistochemistry, and immunoﬂuores-
cence assays Dorsal skin cross-sections from wounds were
stained with hematoxylin and eosin or acidic toluidine blue (to
identify mast cells) using standard methods. Immunohistochemis-
try was performed using anti-macrophage F4/80 antibody (Se-
rotec, Raleigh, North Carolina), anti-neutrophil Ly-6G antibody
(Caltag Laboratories, Burlingame, California), or an anti-BrDU an-
tibody (Beckman Dickinson, San Jose, California), followed by
a biotinylated secondary antibody (Jackson Immunoresearch,
West Grove, Pennsylvania), an ABC reagent (Vector Laboratories,
Burlingame, California), diaminobenzidine (Sigma-Aldrich, St Louis,
Missouri), and a hematoxylin counterstain. Blood vessels were
identified using an anti-CD31 primary antibody (PharmMingen, San
Diego, California), an alexafluor 488 secondary antibody (Molecular
Probes, Eugene, Oregon), and a DAPI counterstain (Vector Labs).
Blood vessels were counted in CD31 labeled sections in a
 20 microscopic field centered on the wound. Neutrophils, ma-
crophages, and mast cells were counted in sections following his-
tochemistry or immunohistochemistry. At least three high-power
fields immediately adjacent to the wound site were quantified and
averaged. BrDU incorporation was quantified by counting BrDU-
labeled nuclei in the basal keratinocyte layer adjacent to wound
margins. BrDU-labeled nuclei were counted beginning with the
BrDU-labeled keratinocyte most proximal to the wound margin and
ending with the BrDU-labeled keratinocyte at which the basal
BrDU labeling index fell below 10%. Basal keratinocyte segments
away from the wound site exhibited a labeling index of 5% or less.
Keratinocyte migration into the wound was measured in each
wound margin from the migrating tip of basal keratinocytes to the
nearest BrDU-labeled basal keratinocyte of the same wound mar-
gin using an ocular micrometer. All measurements were made with
the investigator blinded as to the identity of the samples.
Migration assay Equal numbers of EGFR null- and wild-type ker-
atinocytes were plated separately in wells with S-MEM (Invitrogen,
Carlsbad, California) containing 8% fetal calf serum (Gemini,
Odenville, Alabama) with a calcium concentration adjusted to
0.24 mM. The next day, the medium was replaced with standard
medium consisting of S-MEM with 8% fetal calf serum and a cal-
cium concentration of 0.05 mM. At confluence, keratinocytes were
refed with standard growth medium containing mitomycin C,
standard medium containing mitomycin C and 1 ng per mL TGF-a,
or standard medium containing mitomycin C and 1 ng per mL KGF.
Scratches were made into the culture surface using a sterile pi-
pette tip. Five to eight marked locations of the scratched area in
each dish were photographed and the distance between the mi-
grating epithelial fronts measured. Serial photographs were taken
at several time points from the same location.
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